The Immunology Core I was originally established as the Molecular Immunology Core with three subcores focused on humoral immunity, cellular immunity, and flow-based assays. The mission of this Core is to develop, refine, and provide by training and technology-transfer state-of-the-art immunological assays to evaluate and quantify humoral and cellular responses to support NIH-sponsored AIDS research and training. The assays, reagents, and training offered by the Core are designed to support basic, clinical, and translational research in the prevention, detection, and treatment of HIV infection and AIDS. During the last five years, this Immunology Core has significantly increased its user base, with an overall 3.9-fold increase in total users from 21 to 82, and a 5.4-fold increase in support of local users (60% of total) and a 2.8-fold increase in non-local users (40% of total). Since 2002, the Immunology Core has continuously worked to expand its impact by focusing on the training of investigators in the use of the Core's technologies. As an example of these activities, we developed a hands-on workshop entitled """"""""Research ELISA Assays: The Practical Guide"""""""" in Nairobi, Kenya, February 14-25, 2005. Highlights of research progress during the last five years have included studies on HIV Envelope tropism, Envelope variation and its relationship to the development of neutralizing antibodies (NAbs), the role of antibodies in perinatal transmission in nonhuman primates, examination of the role of IgG with ADCC activity in newborn macaques, hepatitis C-specific T cell responses and phenotypic analysis of liver NK T cells, gamma-delta T cell involvement in the viral immune control of chronic human herpesvirus-8 (HHV8) infection, epitope-specific T cell proliferation in HIV-infected subjects with long-term nonprogression, detailed examination of T cell responses to HIV-2, novel scaffold approaches to present HIV Envelope epitopes as vaccines, and support of translational studies. Over the next five years, we propose: (1) continuous development of state-of-the art assays within a more streamlined organization with two cores located in two, rather than three, locations;(2) the inclusion of a new Core Manager;(3) a redistributed budget to support a higher level of personnel to provide expanded services to a wider group of users;(4) linkages to a new Protein Core at the Seattle Biomedical Research Institute to obtain materials in a more cost-effective manner;and (5) a stronger focus on outreach, with training sessions for individual investigators and technical workshops for groups requesting services to transfer technology and reagents.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI027757-23
Application #
8080969
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2010-06-01
Budget End
2011-05-31
Support Year
23
Fiscal Year
2010
Total Cost
$177,142
Indirect Cost
Name
University of Washington
Department
Type
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372
Fredericksen, Rob J; Mayer, Kenneth H; Gibbons, Laura E et al. (2018) Development and Content Validation of a Patient-Reported Sexual Risk Measure for Use in Primary Care. J Gen Intern Med 33:1661-1668
Wilson, Kate S; Wanje, George; Masese, Linnet et al. (2018) A Prospective Cohort Study of Fertility Desire, Unprotected Sex, and Detectable Viral Load in HIV-Positive Female Sex Workers in Mombasa, Kenya. J Acquir Immune Defic Syndr 78:276-282
Grover, Surbhi; Desir, Fidel; Jing, Yuezhou et al. (2018) Reduced Cancer Survival Among Adults With HIV and AIDS-Defining Illnesses Despite No Difference in Cancer Stage at Diagnosis. J Acquir Immune Defic Syndr 79:421-429
Gómez, Laurén A; Crowell, Claudia S; Njuguna, Irene et al. (2018) Improved Neurodevelopment After Initiation of Antiretroviral Therapy in Human Immunodeficiency Virus-infected Children. Pediatr Infect Dis J 37:916-922
Ikoma, Minako; Gantt, Soren; Casper, Corey et al. (2018) KSHV oral shedding and plasma viremia result in significant changes in the extracellular tumorigenic miRNA expression profile in individuals infected with the malaria parasite. PLoS One 13:e0192659
Lohman-Payne, Barbara; Gabriel, Benjamin; Park, Sangshin et al. (2018) HIV-exposed uninfected infants: elevated cord blood Interleukin 8 (IL-8) is significantly associated with maternal HIV infection and systemic IL-8 in a Kenyan cohort. Clin Transl Med 7:26
McGrath, Christine J; Singa, Benson; Langat, Agnes et al. (2018) Non-disclosure to male partners and incomplete PMTCT regimens associated with higher risk of mother-to-child HIV transmission: a national survey in Kenya. AIDS Care 30:765-773
Thomson, Kerry A; Dhanireddy, Shireesha; Andrasik, Michele et al. (2018) Fertility desires and preferences for safer conception strategies among people receiving care for HIV at a publicly-funded clinic in Seattle, WA. AIDS Care 30:121-129
Stone, Mars; Bainbridge, John; Sanchez, Ana M et al. (2018) Comparison of Detection Limits of Fourth- and Fifth-Generation Combination HIV Antigen-Antibody, p24 Antigen, and Viral Load Assays on Diverse HIV Isolates. J Clin Microbiol 56:

Showing the most recent 10 out of 1275 publications